Press Releases

FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." This clinical trial application is submitted for review by a human ethics

Allegria Therapeutics ("ALLEGRIA"), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today a Seed Financing of USD 3.5 Million by founding investor Forty51 Ventures. Furthermore, the company announced the appointment of co-founder Maria van Dongen, PhD as Chief Executive Officer. Dr. van Dongen brings broad industry experience with a strong track record in Pharma. She previously held positions at amongst

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced, after review of all available safety data, the Company initiated screening of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months. The study protocol has been amended to i

Henlius Biotech, Inc. announced that the Company's commercial partner, Accord BioPharma Inc., has received approval from the United States Food and Drug Administration for HERCESSI™ (HLX02, trastuzumab-strf, biosimilar of Herceptin ® trade name: HANQUYOU in China and Zercepac ® in Europe ), a trastuzumab biosimilar developed and manufactured by Henlius. The product was approved in the United States for the adjuvant treatment of HER2-overexpressing breast cancer, the treatmen

AEON Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. The primary endpoint of mean reduction in monthly migraine days (MMD) over the period 13-24 w

Alpha-9 Oncology, a clinical stage company developing radiopharmaceuticals for the treatment of cancer patients worldwide, announced today that the first participant has been dosed in the Phase 1 study evaluating 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor (MC1R) for the imaging of locally advanced or metastatic melanoma. MC1R expression is known to be elevated in malignant melanoma and other types of skin cancers. The Phase 1 multi-centre study is evaluating t

Arrowhead Pharmaceuticals, Inc. today announced a $50 million milestone payment was received from Royalty Pharma plc. This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2024) was held in Amsterdam, the Netherlands on 22-23 April. The event fostered connections and collaborations of key decision-makers, propelling the market forward with advancements in pharmaceutical manufacturing processes and packaging solutions. PHARMAP 2024 brought togeth

Arsenal Biosciences, Inc., a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC). AB-2100 utilizes ArsenalBio’s CITE (CRISPR Integration of Transgenes by Electroporation) technology to engineer T cells to selectively target the tumor and overc

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the dosing of the first patient in a long-term extension of the ongoing pivotal APOLLOE4 Phase 3 trial of 265 mg oral tablet of ALZ-801/valiltramiprosate, administered twice daily, in Early AD subjects carrying two copies of the ε4 allele of th